UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 22, 2013

 

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware  

(State or other jurisdiction

of incorporation)

 

  
001-16633   84-1460811

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

       

 

3200 Walnut Street, Boulder, Colorado 80301

(Address of principal executive offices) (Zip Code)

 

303-381-6600

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

 

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

 

Item 8.01 Other Events.

 

On October 22, 2013, Array BioPharma issued a press release titled, “ASTRAZENECA INITIATES PHASE 3 CLINICAL TRIAL FOR SELUMETINIB IN NON-SMALL CELL LUNG CANCER.”

 

A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release titled, “ASTRAZENECA INITIATES PHASE 3 CLINICAL TRIAL FOR SELUMETINIB IN NON-SMALL CELL LUNG CANCER.”

 

 

 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: October 22, 2013

Array BioPharma Inc.

 

 

By:  /s/ R. Michael Carruthers

R. Michael Carruthers

Chief Financial Officer

 

 

 
 

 

EXHIBIT INDEX

 

 

Exhibit No.   Description
   
99.1   Press Release titled, “ASTRAZENECA INITIATES PHASE 3 CLINICAL TRIAL FOR SELUMETINIB IN NON-SMALL CELL LUNG CANCER.”